IDEXX Laboratories Management

Management Kriterienprüfungen 3/4

IDEXX Laboratories CEO ist Jay Mazelsky , ernannt in Jun 2019, hat eine Amtszeit von 5.42 Jahren. Die jährliche Gesamtvergütung beträgt $11.52M , bestehend aus 8.7% Gehalt und 91.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.1% der Aktien des Unternehmens, im Wert von MX$698.41M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.4 Jahre bzw. 7.7 Jahre.

Wichtige Informationen

Jay Mazelsky

Geschäftsführender

US$11.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	8.7%
Amtszeit als Geschäftsführer	5.4yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	5.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jay Mazelsky im Vergleich zu den Einnahmen von IDEXX Laboratories verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$866m
Jun 30 2024	n/a	n/a	US$846m
Mar 31 2024	n/a	n/a	US$867m
Dec 31 2023	US$12m	US$1m	US$845m
Sep 30 2023	n/a	n/a	US$823m
Jun 30 2023	n/a	n/a	US$791m
Mar 31 2023	n/a	n/a	US$699m
Dec 31 2022	US$10m	US$1m	US$679m
Sep 30 2022	n/a	n/a	US$670m
Jun 30 2022	n/a	n/a	US$664m
Mar 31 2022	n/a	n/a	US$735m
Dec 31 2021	US$9m	US$977k	US$745m
Sep 30 2021	n/a	n/a	US$757m
Jun 30 2021	n/a	n/a	US$728m
Mar 31 2021	n/a	n/a	US$674m
Dec 31 2020	US$7m	US$814k	US$582m
Sep 30 2020	n/a	n/a	US$497m
Jun 30 2020	n/a	n/a	US$460m
Mar 31 2020	n/a	n/a	US$437m
Dec 31 2019	US$7m	US$632k	US$428m
Sep 30 2019	n/a	n/a	US$423m
Jun 30 2019	n/a	n/a	US$407m
Mar 31 2019	n/a	n/a	US$390m
Dec 31 2018	US$3m	US$555k	US$377m
Sep 30 2018	n/a	n/a	US$330m
Jun 30 2018	n/a	n/a	US$307m
Mar 31 2018	n/a	n/a	US$284m
Dec 31 2017	US$2m	US$469k	US$263m

Vergütung im Vergleich zum Markt: JayDie Gesamtvergütung ($USD11.52M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MX ($USD5.73M).

Entschädigung vs. Einkommen: JayDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jay Mazelsky (63 yo)

5.4yrs

Amtszeit

US$11,519,309

Vergütung

Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Mazelsky	President	5.4yrs	US$11.52m	0.10% MX$ 698.4m
Brian McKeon	CFO, Executive VP & Treasurer	10.8yrs	US$3.85m	0.060% MX$ 418.6m
Michael Lane	Executive VP and GM of Reference Laboratories & Information Technology	4.8yrs	US$2.92m	0.0086% MX$ 60.1m
John Hart	Senior Vice President of Global Operations	7.2yrs	keine Daten	keine Daten
Jeffery Chadbourne	Senior Vice President of Commercial Finance & Sales Operations	9.8yrs	keine Daten	keine Daten
Martin Smith	Executive VP & CTO	3.3yrs	keine Daten	keine Daten
Ken Grady	Senior VP & Chief Information Officer	8.8yrs	keine Daten	keine Daten
Sharon Underberg	Executive VP	no data	US$1.88m	0.0068% MX$ 47.8m
Michael Johnson	Executive VP & Chief Human Resources Officer	2.7yrs	keine Daten	0.00022% MX$ 1.5m
George Fennell	Senior VP & Chief Revenue Officer	no data	keine Daten	0.0084% MX$ 59.1m
Michael Erickson	Executive VP and GM of Point of Care Diagnostics & Telemedicine	no data	keine Daten	0.013% MX$ 91.0m
Murthy Yerramilli	Senior Vice President of Research & Development	4.8yrs	keine Daten	keine Daten

5.4yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: IDXX *Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Mazelsky	President	5.1yrs	US$11.52m	0.10% MX$ 698.4m
M. Szostak	Independent Director	12.3yrs	US$367.66k	0.0074% MX$ 51.8m
Daniel Junius	Independent Director	10.7yrs	US$362.66k	0.0031% MX$ 21.8m
Bruce Claflin	Independent Director	9.3yrs	US$367.66k	0.0021% MX$ 14.7m
Stuart Essig	Independent Director	7.3yrs	US$350.16k	0.0024% MX$ 16.9m
Lawrence Kingsley	Independent Non-Executive Chairman	8.1yrs	US$495.02k	0.0096% MX$ 67.4m
Sophie Vandebroek	Independent Director	11.3yrs	US$335.16k	0.011% MX$ 76.9m
Irene Chang Britt	Independent Director	1.3yrs	US$258.89k	0.00025% MX$ 1.7m
Sam Samad	Independent Director	5.3yrs	US$342.66k	0% MX$ 0
Asha Collins	Independent Director	4yrs	US$335.16k	0.00095% MX$ 6.6m

7.7yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: IDXX *Die Vorstandsmitglieder gelten als erfahren (7.7 Jahre durchschnittliche Amtszeit).

IDEXX Laboratories Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes

Independent Director recently sold Mex$4.7m worth of stock

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

Insufficient new directors

Insufficient new directors

Recent updates

IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.83 (vs US$2.55 in 3Q 2023)

Independent Director recently sold Mex$4.7m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$2.46 (vs US$2.70 in 2Q 2023)

IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Insufficient new directors

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold Mex$52m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Insufficient new directors

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold Mex$2.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

President recently sold Mex$81m worth of stock

Insider recently sold Mex$142m worth of stock

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Independent Director has left the company

Senior Advisor & Director recently sold Mex$5.5m worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold Mex$3.3m worth of stock

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter